Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowNet Cash FlowOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RAPT Therapeutics (RAPT) Capital Expenditures: 2020-2024

Historic Capital Expenditures for Therapeutics (RAPT) over the last 5 years, with Dec 2024 value amounting to $1,000.

  • Therapeutics' Capital Expenditures fell 98.51% to $1,000 in Q4 2024 from the same period last year, while for Dec 2024 it was $122,000, marking a year-over-year decrease of 89.16%. This contributed to the annual value of $122,000 for FY2024, which is 89.16% down from last year.
  • Latest data reveals that Therapeutics reported Capital Expenditures of $1,000 as of Q4 2024, which was down 94.12% from $17,000 recorded in Q3 2024.
  • Over the past 5 years, Therapeutics' Capital Expenditures peaked at $759,000 during Q1 2023, and registered a low of -$1,000 during Q2 2024.
  • Moreover, its 3-year median value for Capital Expenditures was $74,000 (2022), whereas its average is $174,333.
  • Its Capital Expenditures has fluctuated over the past 5 years, first surged by 784.38% in 2022, then plummeted by 100.43% in 2024.
  • Over the past 5 years, Therapeutics' Capital Expenditures (Quarterly) stood at $174,000 in 2020, then soared by 126.44% to $394,000 in 2021, then crashed by 87.56% to $49,000 in 2022, then soared by 36.73% to $67,000 in 2023, then crashed by 98.51% to $1,000 in 2024.
  • Its last three reported values are $1,000 in Q4 2024, $17,000 for Q3 2024, and -$1,000 during Q2 2024.